Biogen Idec Deeply Undervalued
Biogen Idec Inc. (BIIB - Analyst Report) posted solid results in the third quarter of 2008, despite the slowdown in Tysabri sales due to fears of PML. We think the Biogen core business will remain strong over the next several quarters, and that Tysabri prescriptions will resume their previous pace shortly.
In the meantime, the name is significantly undervalued and would be a very attractive takeout candidate for a large-cap pharmaceutical company looking for a great phase-III pipeline. We expect 2009 to be an eventful year on the pipeline front.
As investors become more comfortable with both Tysabri trends and Biogen's emerging pipeline, we believe shares will recover back into the high $50's. At today's price, the name is too attractive to ignore.
Read the full analyst report on BIIB.
|
|
|
Share |
RSS |
Rate Pos |
Rate Neg |
Comment |
|
|
||||||
Free Stock Analysis From Zacks
Includes Zacks Long-Term Recommendation and Target Price
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
- Free Four Zacks #1 Rank "Strong Buy" Stocks
- Free Timely Market Commentary
- Free Wealth Management Tips
- Free Profitable Strategy Screens
- Free Bull and Bear Stocks of the Day
Zacks FREE Registration
X Close
Loading Stories...Most Popular on Zacks.com
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | Feb 10, 2010 09:44 am ET |

Sponsored Links 
0.63 %

-61.75
[CLICK TO CLOSE X]